39
Views
0
CrossRef citations to date
0
Altmetric
Letter to the editor

Letter to the editor concerning the pharmacological management of behavioral disturbances in patients with Alzheimer’s disease

References

  • Lozupone M, La Montagna M, Sardone R, et al. Can pharmacotherapy effectively reduce Alzheimer’s related agitation? Expert Opin Pharmacother. 2020 Jun 1;1–6. DOI:10.1080/14656566.2020.1770730. *The subject of this letter to the Editor.
  • Nagata T, Shinagawa S, Nakajima S, et al. Pharmacological management of behavioral disturbances in patients with Alzheimer’s disease. Expert Opin Pharmacother. 2020;21(9):1093–1102.*The subject of this letter to the Editor.
  • Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin. 1907 Jan;64:146–148.
  • Tariot PN, Blazina L. The psychopathology of dementia. In: Morris J, editor. Handbook of dementing illnesses. New York, NY: Marcel Dekker; 1993. p. 461–475.
  • Wilson RS, Mendes de Leon CF, Barnes LL, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA. 2002;287(6):742–748.
  • Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer’s disease: seeking the neurobiological basis. Neurobiol Aging. 2000;21:845–861.
  • Kosel F, Pelley JMS, Franklin TB. Behavioural and psychological symptoms of dementia in mouse models of Alzheimer’s disease-related pathology. Neurosci Biobehav Rev. 2020;112:634–647.
  • Zhang Q, Yang C, Liu T, et al. Citalopram restores short-term memory deficit and non-cognitive behaviors in APP/PS1 mice while halting the advance of Alzheimer’s disease-like pathology. Neuropharmacology. 2018;131:475–486.
  • Porsteinsson AP, Drye LT, Pollack BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–691.
  • Bangen KJ, Nation DA, Delano-Wood L, et al. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer’s disease. Alzheimers Dement. 2015 Apr;11(4):394–403.
  • Toyama K, Spin JM, Mogi M, et al. Therapeutic perspective on vascular cognitive impairment. Pharmacol Res. 2019Aug;146:104266.
  • Victoroff J, Lin FV, Coburn KL, et al. Noncognitive behavioral changes associated with Alzheimer’s disease: implications of neuroimaging findings. J Neuropsychiatry Clin Neurosci. 2018;30(1):14–21.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.